How to Claim Damages for Zoetis Stock Losses in Recent Lawsuit

If you purchased Zoetis stock between January 14, 2025 and May 6, 2026, you may be entitled to recover damages through an ongoing securities class action lawsuit. The case alleges that Zoetis failed to disclose material information about declining product adoption and market share losses before significant stock price drops occurred. For example, an investor who purchased 500 shares at $111 per share in early January 2025 and held through May 2026 would have experienced roughly $12,000 in losses on that position alone as the stock fell to $87.31.

You don’t need to pay upfront legal fees to pursue this claim. The law firms handling the case work on a contingency basis, meaning you pay nothing unless there is a recovery. The key deadline you need to know about is July 27, 2026, when investors must notify the court if they wish to serve as lead plaintiff in the case.

WHAT IS THE ZOETIS STOCK LOSS LAWSUIT AND WHO CAN FILE?
ELIGIBILITY REQUIREMENTS AND THE LEAD PLAINTIFF DEADLINE
UNDERSTANDING THE STOCK PRICE DECLINES AND DAMAGE CALCULATIONS
GATHERING YOUR DOCUMENTATION AND PROVING YOUR PURCHASE
THE CONTINGENCY FEE ARRANGEMENT AND POTENTIAL RISKS
WHAT THE ALLEGED MISCONDUCT INVOLVED
NAVIGATING THE CLAIMS PROCESS AND NEXT STEPS

WHAT IS THE ZOETIS STOCK LOSS LAWSUIT AND WHO CAN FILE?

The zoetis securities class action focuses on allegations that the company and its executives misled investors about the health and performance of key product lines. According to the complaint, Zoetis failed to disclose that prescription adoption of Librela, its canine pain management treatment, was weakening significantly due to FDA safety warnings about serious neurological side effects in dogs. The company also allegedly concealed that Simparica Trio, its parasiticide product, was losing market share to competitors and that its dermatology products faced similar competitive pressures.

Any person or entity that purchased Zoetis securities during the class period is potentially eligible to participate in the lawsuit, regardless of whether you still own the stock. You may have purchased through a brokerage account, a 401(k) plan, an IRA, or any other investment vehicle. If you sold those shares at a loss or are still holding shares that have declined in value, you could be entitled to compensation if the lawsuit succeeds or settles.

ELIGIBILITY REQUIREMENTS AND THE LEAD PLAINTIFF DEADLINE

To have standing in this lawsuit, you must have purchased Zoetis stock during the specific class period: January 14, 2025 through May 6, 2026. This window is critical—purchases made before January 14, 2025 or after May 6, 2026 typically fall outside the scope of the class action and may not be recoverable through this particular case. The date parameters exist because these are the dates when the alleged misstatements were supposedly in effect and before the truth emerged.

The lead plaintiff deadline of July 27, 2026 is a hard cutoff with real consequences. If you want to serve as the lead plaintiff—meaning you would represent the entire class of injured investors and have more input into the case direction—you must file a motion with the court by this date. Investors with substantial losses exceeding $100,000 are particularly encouraged to step forward. However, even if you miss this deadline, you can still participate in the class action as a non-lead plaintiff and receive your proportionate share of any recovery.

UNDERSTANDING THE STOCK PRICE DECLINES AND DAMAGE CALCULATIONS

The lawsuit was triggered by specific, dramatic stock price movements that revealed new information to the market. On November 4, 2025, Zoetis stock fell $19.89 per share in a single day, closing at $124.46—a 13.8 percent decline. This decline suggests the market was reacting to negative news about one or more of the company’s major products.

Then, on May 7, 2026, the stock experienced an even steeper drop of $23.91 per share, closing at $87.31—a 21.5 percent plunge that represents a fundamental reassessment of the company’s value. When you calculate potential damages, you need to understand that the lawsuit is built on the premise that the stock was artificially inflated due to Zoetis’s alleged concealment of negative information. The overall decline from January 2025 to May 2026 totaled approximately $24 per share as the stock fell from $111.22 to $87.31. This means an investor who bought 1,000 shares would have experienced approximately $24,000 in paper losses during this period, all of which may be compensable if the lawsuit succeeds.

GATHERING YOUR DOCUMENTATION AND PROVING YOUR PURCHASE

To claim damages, you’ll need to provide proof of your Zoetis purchases during the class period. Specifically, you must compile brokerage statements or trade confirmations that show the exact purchase dates, the number of shares purchased, the prices you paid, and—if applicable—the dates and prices when you sold those shares. This documentation is essential because the law firms and court need to verify that you were actually harmed during the specified class period.

If you no longer have access to your original confirmations, most brokerage firms maintain transaction history in their online portals or can issue historical statements upon request. For shares held in retirement accounts like 401(k)s or IRAs, you may need to contact your plan administrator to obtain records. Many plan administrators keep transaction history for at least seven years. The comparison is straightforward: if you have records showing you bought at $110 and sold at $90, your loss per share is $20 times the number of shares.

THE CONTINGENCY FEE ARRANGEMENT AND POTENTIAL RISKS

One of the most important protections in securities class actions is the contingency fee structure. You will not owe the law firms any out-of-pocket legal fees. Instead, the attorneys collect their fees only if the case settles or goes to judgment and a recovery is obtained. Typically, this means the law firms receive a percentage of the settlement fund (often 25 to 33 percent) and the court must approve those fees before they’re deducted. Your settlement proceeds are calculated based on your documented losses, and you receive your proportionate share.

However, there are limitations and risks you should understand. First, there is no guarantee that the lawsuit will succeed or that any settlement will be reached. Securities litigation is complex, and defendants often have strong legal defenses. Second, even if damages are awarded, the amount recovered may be far less than your actual losses because the total settlement fund must be divided among all eligible investors. For example, if the total settlement is $50 million and there are 100,000 eligible claimants with documented losses totaling $500 million, each dollar of loss might recover only ten cents.

WHAT THE ALLEGED MISCONDUCT INVOLVED

The specific allegations in the complaint center on three major product categories where Zoetis allegedly failed to disclose deteriorating conditions. Librela is designed to treat canine osteoarthritis pain and represents an important revenue stream for the company’s companion animal health division. The lawsuit alleges that Zoetis knew prescription adoption was declining sharply due to FDA safety communications about serious neurological complications but didn’t inform investors of this fact.

Simparica Trio, another major product for flea and tick prevention in dogs, supposedly lost significant market share to competing parasiticides without adequate disclosure to the investment community. The dermatology portfolio allegation follows a similar pattern: new competing treatments entered the market and captured share from Zoetis products, but the company allegedly minimized the competitive threat in its public communications. None of these competitive challenges are unusual in pharmaceutical or animal health markets, but the accusation is specifically that Zoetis had material knowledge about the magnitude and speed of these declines and failed to share that information with investors when it was legally required to do so.

NAVIGATING THE CLAIMS PROCESS AND NEXT STEPS

Once you’ve identified that you purchased Zoetis stock during the class period and have gathered your documentation, the next step is to contact one of the law firms handling the case. Multiple firms are actively working on this class action, and you can find contact information through their firm websites. Some firms maintain dedicated case pages with instructions for submitting claims, while others require you to call or email directly.

When you reach out, have your brokerage statements ready to provide. The law firms or their claims administrator will guide you through the submission process, which typically involves completing a claim form and mailing it in or uploading it through an online portal. The deadline for submitting claims will be established by the court and announced in settlement notices, but don’t wait until the last possible moment. Earlier submissions allow the claims administrator time to verify your documentation and contact you if any information is missing or unclear.